Medpace Holdings (MEDP) stock
NASDAQ
As of the Nov 13, 2026 close (U.S. Eastern)
- Market cap
- $18.3B
- As of Nov 13, 2026
- P/E
- 35.42x
- Trailing twelve months
- P/B
- 31.30x
- Latest reported equity
- P/S
- 6.45x
- Trailing twelve months
- ROE
- 88.4%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
- Market cap
- $18.3B
- As of Nov 13, 2026
- P/E
- 35.42x
- Trailing twelve months
- P/B
- 31.30x
- Latest reported equity
- P/S
- 6.45x
- Trailing twelve months
- ROE
- 88.4%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
35.42x
P/B
31.30x
P/S
6.45x
Earnings and dividend metrics▾
Earnings
EPS
$18.46
Earnings per share
BPS
$20.89
Book value per share
ROE
88.4%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned $18.46 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $20.89 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 88.4%.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue increased 8.5% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $660M+8.5%
$533M
Jul–Sep '24
$660M
Jul–Sep '25
$716M
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Oct 22, 2026.
- Earnings per share increased 25.4% from the same quarter a year earlier.
- Revenue increased 8.5% from the same quarter a year earlier.
- Operating income increased 16.9% from the same quarter a year earlier.
- Net income increased 23.4% from the same quarter a year earlier.
Filed Oct 22, 2026 · 10-Q · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- EWALD STEPHEN PGeneral Counsel & Corp. Secy. · Oct 29, 2026Open-market sale1,245 shares · $859KAvg. price $69019,098 shares held after
- BURWIG SUSAN EExec. VP, Operations · Oct 27, 2026Open-market sale3,940 shares · $2.7MAvg. price $67754,012 shares held after
- BURWIG SUSAN EExec. VP, Operations · Oct 26, 2026Open-market sale16,060 shares · $10.9MAvg. price $67757,624 shares held after
- BURWIG SUSAN EExec. VP, Operations · Oct 26, 2026Option exercise328 shares · $55KAvg. price $166.7357,952 shares held after
- BURWIG SUSAN EExec. VP, Operations · Oct 21, 2026Option exercise2,700 shares · $450KAvg. price $166.7373,684 shares held after
- BURWIG SUSAN EExec. VP, Operations · Oct 12, 2026Option exercise3,000 shares · $500KAvg. price $166.7370,984 shares held after
- BURWIG SUSAN EExec. VP, Operations · Oct 7, 2026Option exercise2,000 shares · $333KAvg. price $166.7367,984 shares held after
- Troendle August J.President & CEO · Sep 30, 2026Open-market sale21,966 shares · $13.7MAvg. price $625.47338,225 shares held after
- Carley Brian TDirector · Sep 30, 2026Option exercise36 shares27,861 shares held after
- Kraft Robert O.Director · Sep 30, 2026Option exercise32 shares987 shares held after
- McCarthy Cornelius P. IIIDirector · Sep 30, 2026Option exercise28 shares12,303 shares held after
- Troendle August J.President & CEO · Sep 29, 2026Open-market sale26,701 shares · $16.6MAvg. price $621.02360,191 shares held after
- Troendle August J.President & CEO · Sep 28, 2026Open-market sale2,410 shares · $1.5MAvg. price $620.07386,892 shares held after
- Troendle August J.President & CEO · Sep 25, 2026Open-market sale154 shares · $96KAvg. price $620.6389,302 shares held after
- Troendle August J.President & CEO · Sep 24, 2026Open-market sale27,833 shares · $17.3MAvg. price $621.33389,456 shares held after
- Troendle August J.President & CEO · Sep 23, 2026Open-market sale16,083 shares · $10.1MAvg. price $628.64417,289 shares held after
- Troendle August J.President & CEO · Sep 22, 2026Open-market sale49,018 shares · $30.8MAvg. price $628.11433,372 shares held after
- Troendle August J.President & CEO · Sep 21, 2026Open-market sale21,883 shares · $13.6MAvg. price $623.29482,390 shares held after
- Troendle August J.President & CEO · Sep 17, 2026Open-market sale10,880 shares · $6.7MAvg. price $620.4504,273 shares held after
- Troendle August J.President & CEO · Sep 16, 2026Open-market sale8,770 shares · $5.4MAvg. price $621.29515,153 shares held after
- Troendle August J.President & CEO · Sep 15, 2026Open-market sale15,971 shares · $9.9MAvg. price $620.84523,923 shares held after
- BURWIG SUSAN EExec. VP, Operations · Sep 15, 2026Option exercise3,000 shares · $500KAvg. price $166.7365,984 shares held after
- Troendle August J.President & CEO · Aug 27, 2026Open-market sale650 shares · $403KAvg. price $620.27539,894 shares held after
- Troendle August J.President & CEO · Aug 26, 2026Open-market sale4,000 shares · $2.5MAvg. price $620.03540,544 shares held after
- Kraft Robert O.Director · Aug 26, 2026Open-market sale3,858 shares · $2.4MAvg. price $617.81955 shares held after
- Kraft Robert O.Director · Aug 26, 2026Option exercise3,858 shares · $325KAvg. price $84.364,813 shares held after
- Troendle August J.President & CEO · Aug 25, 2026Open-market sale673 shares · $418KAvg. price $620.38544,544 shares held after
- Troendle August J.President & CEO · Aug 24, 2026Open-market sale1,983 shares · $1.2MAvg. price $620.23545,217 shares held after
- Troendle August J.President & CEO · Aug 21, 2026Open-market sale13,995 shares · $8.7MAvg. price $624.45547,200 shares held after
- Troendle August J.President & CEO · Aug 20, 2026Open-market sale27,174 shares · $16.8MAvg. price $618.79561,195 shares held after
- Brady Kevin M.CFO & Treasurer · Aug 20, 2026Open-market sale3,400 shares · $2.1MAvg. price $625.2412,830 shares held after
- Brady Kevin M.CFO & Treasurer · Aug 20, 2026Option exercise3,400 shares · $472KAvg. price $138.8716,230 shares held after
- Troendle August J.President & CEO · Aug 19, 2026Open-market sale15,609 shares · $9.5MAvg. price $606.47588,369 shares held after
- DAVENPORT FRED B JRDirector · Aug 19, 2026Open-market sale7,283 shares · $4.4MAvg. price $606.153,798 shares held after
- Carley Brian TDirector · Aug 19, 2026Open-market sale5,000 shares · $3.0MAvg. price $608.6327,825 shares held after
- DAVENPORT FRED B JRDirector · Aug 19, 2026Option exercise7,583 shares · $880KAvg. price $116.0837
Show 3 price lots
- 3,858 shares × $84.36$325K
- 1,822 shares × $164.68$300K
- 1,903 shares × $133.87$255K
- Troendle August J.President & CEO · Aug 13, 2026Open-market sale458 shares · $275KAvg. price $600.39603,978 shares held after
- Troendle August J.President & CEO · Aug 12, 2026Open-market sale11,366 shares · $6.8MAvg. price $601.53604,436 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsFilings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Medpace Holdings (MEDP) stock information
NASDAQ
Medpace Holdings (MEDP) is listed on NASDAQ. Its market capitalization is about $18.3B. On trailing-twelve-month earnings the P/E ratio is 35.42, and the P/B ratio is 31.3. Return on equity is 88.4%. These figures are computed in-house from official filings and are reference information only.
Medpace Holdings — frequently asked questions
- What is the P/E ratio of Medpace Holdings (MEDP)?
- On a trailing-twelve-month basis, MEDP trades at a P/E ratio of 35.42. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Medpace Holdings?
- MEDP has a market capitalization of about $18.3B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.